iwCLL 2023 | Clinical relevance of intensive laboratory monitoring during venetoclax initiation in CLL

Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses his point of view on whether the recommended period of intensive laboratory monitoring during the standard ramp-up at time of venetoclax initiation for chronic lymphocytic leukemia (CLL) is necessary. From the anecdotal evidence of Dr Shadman in his clinic, few follow-up visits and blood draws lead to interventions in low- and intermediate-risk patients. Dr Shadman believes that generating a hypothesis and prospective study regarding the necessity of laboratory monitoring in low-risk patients may lead to regulatory changes for these individuals and require them to attend fewer follow-up visits during treatment. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.